Program
vebreltinib
Also written as “PLB1001”, “Vebreltinib combined with platinum-based doublet chemotherapy.” and “APL-101 Oral Capsules”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Glioblastoma · Kidney Neoplasms · Glioma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Pearl Biotechnology Limited Liability | 63 open or running | phase 3since Jul 26, 2023 | Aug 16, 2016 | Feb 2029phase 3 · NCT06930794 |
| Apollomics | 21 open or running | phase 2since Jun 1, 2017 | Jun 1, 2017 | none ahead |
| CHABiotech | 10 open or running | phase 1since Sep 15, 2020 | Sep 15, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2016First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Beijing Pearl Biotechnology Limited LiabilityBeijing Pearl Biotechnology Limited Liability · NCT02896231 · 37 enrolled · China
- Nov 28, 2016Phase 1 study in GliomaBeijing Pearl Biotechnology Limited Liability · NCT02978261 · 18 enrolled · China
- Jun 1, 2017Apollomics's first study: phase 2 study in Kidney NeoplasmsNew to ApollomicsApollomics · NCT03175224 · 497 planned · United States, Australia, Canada and more
- Feb 3, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT04258033 · 145 enrolled · China
- Sep 15, 2020CHABiotech's first study: phase 1 study in Solid TumorNew to CHABiotechCHABiotech · NCT04557306 · 6 enrolled · Korea, Republic of
- May 3, 2022Phase 1 study in BioequivalenceApollomics · NCT05367388 · 48 enrolled · New Zealand
- Jul 26, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT05989542 · 136 planned · China
- Oct 24, 2023Phase 3 study in GlioblastomaBeijing Pearl Biotechnology Limited Liability · NCT06105619 · 84 enrolled · China
- Feb 27, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT06930794 · 300 planned · China
Ahead
- Feb 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT06930794
TargetBeta
“An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) ”NCIt, by rule
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| telisotuzumab adizutecan | AbbVie | phase 3 | 18 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| glumetinibrule | Haihe Biopharma | phase 3 | 8 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 7 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06930794Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Beijing Pearl Biotechnology Limited Liability | Feb 2029 | 300 |
| NCT06105619Glioblastoma · China | 3 | Active, not recruiting | Beijing Pearl Biotechnology Limited Liability | Apr 1, 2023 | 84 |
| NCT05989542Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Beijing Pearl Biotechnology Limited Liability | Sep 30, 2026 | 136 |
| NCT05367388Bioequivalence · New Zealand | 1 | UNKNOWN | Apollomics | Nov 2022 | 48 |
| NCT04557306Solid Tumor · Korea, Republic of | 1 | Completed | CHABiotech | Oct 26, 2021 | 6 |
| NCT04258033Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Beijing Pearl Biotechnology Limited Liability | May 14, 2024 | 145 |
| NCT03175224Kidney Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Apollomics | Mar 30, 2026 | 497 |
| NCT02978261Glioma · China | 1 | Completed | Beijing Pearl Biotechnology Limited Liability | Apr 2018 | 18 |
| NCT02896231Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Beijing Pearl Biotechnology Limited Liability | Oct 2019 | 37 |
How it is read
Names in the registry
- “PLB1001”, 5 entries
- “Vebreltinib combined with platinum-based doublet chemotherapy.”, 1 entry
- “APL-101 Oral Capsules”, 1 entry
- “CBT101 cells, every 2 weeks”, 1 entry
- “CBT101 cells, every 4 weeks”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Glioblastoma, 1 study
- Kidney Neoplasms, 1 study
- Glioma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.